G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 14.89 USD -3% Market Closed
Market Cap: 923.6m USD

GH Research PLC
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

GH Research PLC
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
G
GH Research PLC
NASDAQ:GHRS
Total Receivables
$150k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Total Receivables
$675.6m
CAGR 3-Years
-3%
CAGR 5-Years
-10%
CAGR 10-Years
-6%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Total Receivables
$764.4m
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
15%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Total Receivables
$42.4m
CAGR 3-Years
159%
CAGR 5-Years
-2%
CAGR 10-Years
23%
Cosmo Pharmaceuticals NV
SIX:COPN
Total Receivables
€45.8m
CAGR 3-Years
6%
CAGR 5-Years
0%
CAGR 10-Years
-12%
Ovoca Bio PLC
LSE:OVB
Total Receivables
€58k
CAGR 3-Years
-44%
CAGR 5-Years
-19%
CAGR 10-Years
-24%
No Stocks Found

GH Research PLC
Glance View

Market Cap
923.6m USD
Industry
Pharmaceuticals

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

GHRS Intrinsic Value
2.94 USD
Overvaluation 80%
Intrinsic Value
Price
G

See Also

What is GH Research PLC's Total Receivables?
Total Receivables
150k USD

Based on the financial report for Dec 31, 2024, GH Research PLC's Total Receivables amounts to 150k USD.

What is GH Research PLC's Total Receivables growth rate?
Total Receivables CAGR 1Y
-16%

Over the last year, the Total Receivables growth was -16%.

Back to Top